Evidence map›Paper›PMID 31336406›Full record

ArticleNeurogastroenterology and motility2019

µ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients.

Giovanni Dothel, Lin Chang, Wendy Shih, Maria Raffaella Barbaro, Cesare Cremon, Vincenzo Stanghellini, Fabrizio De Ponti, Emeran A Mayer, Giovanni Barbara, Catia Sternini

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurogastroenterology and motility, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Current perspectives on irritable bowel syndrome: a narrative review.The Journal of international medical research · 2022
    Review
  8. Article
  9. Article
  10. Expression and Functions of the CBFrontiers in pharmacology · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Expression of Opioid Receptors in Cells of the Immune System.International journal of molecular sciences · 2020
    Review
  15. Article
  16. Potential neuro-immune therapeutic targets in irritable bowel syndrome.Therapeutic advances in gastroenterology · 2020
    Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Giovanni DothelDivision of Digestive Diseases, Department of Medicine, CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Lin ChangDivision of Digestive Diseases, Department of Medicine, CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Wendy ShihDepartment of Biostatistics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Maria Raffaella BarbaroDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Cesare CremonDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0002-7777-2936
Vincenzo StanghelliniDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0003-0559-4875
Fabrizio De PontiDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Emeran A MayerDivision of Digestive Diseases, Department of Medicine, CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Giovanni BarbaraDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0001-9745-0726
Catia SterniniDivision of Digestive Diseases, Department of Medicine, CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-0492-1993
University of Bologna · ITUniversity of California, Los Angeles · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
Women's Health and Functional Visceral Disorders CenterP50DK064539 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAYER, EMERAN A · 2002 to 2017
$17.5M
NIDDK NIH HHS P30 DK041301NIDDK NIH HHS P50 DK064539
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe gut immune, cannabinoid, and opioid systems constitute an integrated network contributing to visceral sensation and pain modulation. We aimed to assess the expression of the µ-opioid receptor (MOR), its ligand β-endorphin (β-END), and cannabinoid receptor-2 (CB

methodsMucosal biopsies were obtained from the left colon of 31 IBS patients (45% women) with predominant constipation (IBS-C, 9) or diarrhea (IBS-D, 10) or with mixed bowel habits (IBS-M, 12) and 32 AC (44% women) and processed for qRT-PCR, Western blotting, and immunohistochemistry. KEY

resultsµ-opioid receptor and CB

conclusionsThe increased expression of MOR, β-END, and CB

Indexed as

beta-EndorphinFemaleHumansIntestinal MucosaIrritable Bowel SyndromeMaleReceptor, Cannabinoid, CB2Receptors, Opioid, muSex Characteristicsbeta-EndorphinCNR2 protein, humanReceptor, Cannabinoid, CB2Receptors, Opioid, mucannabinoidimmune systemirritable bowel syndromeneuro-immune cross talkopioid

Identifiers

PMID31336406
PMCPMC6791736
OpenAlexW2963358410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.